Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PFE (Pfizer) How high will it go? -- Ignore unavailable to you. Want to Upgrade?

To: Joe S Pack who wrote (8259)	11/4/1999 5:35:00 PM
From: StockHawk	Read Replies (1) \| Respond to of 9523

Nat, I'll take a stab at a few of your questions: >>Will this create pressure on WLA's CEO to meet and discuss with his board? Will he and his friends be happy?<< Of course it will create pressure. However, something here is missing. No question PFE is a better company than AHP, and PFE is offering more money, but the bid is hostile. Why isn't WLA interested in PFE? My speculation: Egos are very important in these dances. PFE did a brilliant job with Lipitor, but WLA probably feels PFE got the better of the deal and is miffed. When WLA tried to renegotiate the terms recently PFE held firm (as they should have). >>What about regulatory hurdles?<< IMHO, no problem. There are many large pharm companies. This deal would not reduce competition in the industry. >>I am sure there will be considerable cost savings from Lipitor and other comarketing.<< I do not think so. The whole reason for a co-promote is that the smaller co does not have the man-power to detail the product. So they go to a larger co with a big sales force. There is little overlap here. Synergies will more likely come from other areas - finance, personnel, regulatory affairs, middle management, etc, and from geographic overlap. >>I am a long term core holder but want to see in 50s.<< So does just about everyone, including, I imagine, Bill Steere. StockHawk